S&P 500   4,584.15 (+0.77%)
DOW   36,124.07 (+0.19%)
QQQ   390.77 (+1.49%)
AAPL   194.91 (+1.35%)
MSFT   370.89 (+0.57%)
META   327.05 (+3.02%)
GOOGL   138.29 (+6.36%)
AMZN   147.68 (+2.19%)
TSLA   240.87 (+0.63%)
NVDA   463.81 (+1.93%)
NIO   7.44 (-4.00%)
BABA   72.16 (+0.94%)
AMD   126.59 (+8.36%)
T   17.09 (+0.89%)
F   10.80 (+1.03%)
MU   73.65 (+0.71%)
CGC   0.73 (+4.93%)
GE   118.25 (-1.30%)
DIS   93.07 (+1.72%)
AMC   6.85 (+0.88%)
PFE   28.77 (-0.07%)
PYPL   58.37 (-1.95%)
XOM   98.62 (-0.49%)
S&P 500   4,584.15 (+0.77%)
DOW   36,124.07 (+0.19%)
QQQ   390.77 (+1.49%)
AAPL   194.91 (+1.35%)
MSFT   370.89 (+0.57%)
META   327.05 (+3.02%)
GOOGL   138.29 (+6.36%)
AMZN   147.68 (+2.19%)
TSLA   240.87 (+0.63%)
NVDA   463.81 (+1.93%)
NIO   7.44 (-4.00%)
BABA   72.16 (+0.94%)
AMD   126.59 (+8.36%)
T   17.09 (+0.89%)
F   10.80 (+1.03%)
MU   73.65 (+0.71%)
CGC   0.73 (+4.93%)
GE   118.25 (-1.30%)
DIS   93.07 (+1.72%)
AMC   6.85 (+0.88%)
PFE   28.77 (-0.07%)
PYPL   58.37 (-1.95%)
XOM   98.62 (-0.49%)
S&P 500   4,584.15 (+0.77%)
DOW   36,124.07 (+0.19%)
QQQ   390.77 (+1.49%)
AAPL   194.91 (+1.35%)
MSFT   370.89 (+0.57%)
META   327.05 (+3.02%)
GOOGL   138.29 (+6.36%)
AMZN   147.68 (+2.19%)
TSLA   240.87 (+0.63%)
NVDA   463.81 (+1.93%)
NIO   7.44 (-4.00%)
BABA   72.16 (+0.94%)
AMD   126.59 (+8.36%)
T   17.09 (+0.89%)
F   10.80 (+1.03%)
MU   73.65 (+0.71%)
CGC   0.73 (+4.93%)
GE   118.25 (-1.30%)
DIS   93.07 (+1.72%)
AMC   6.85 (+0.88%)
PFE   28.77 (-0.07%)
PYPL   58.37 (-1.95%)
XOM   98.62 (-0.49%)
S&P 500   4,584.15 (+0.77%)
DOW   36,124.07 (+0.19%)
QQQ   390.77 (+1.49%)
AAPL   194.91 (+1.35%)
MSFT   370.89 (+0.57%)
META   327.05 (+3.02%)
GOOGL   138.29 (+6.36%)
AMZN   147.68 (+2.19%)
TSLA   240.87 (+0.63%)
NVDA   463.81 (+1.93%)
NIO   7.44 (-4.00%)
BABA   72.16 (+0.94%)
AMD   126.59 (+8.36%)
T   17.09 (+0.89%)
F   10.80 (+1.03%)
MU   73.65 (+0.71%)
CGC   0.73 (+4.93%)
GE   118.25 (-1.30%)
DIS   93.07 (+1.72%)
AMC   6.85 (+0.88%)
PFE   28.77 (-0.07%)
PYPL   58.37 (-1.95%)
XOM   98.62 (-0.49%)

Clene Stock Price, News & Analysis (NASDAQ:CLNN)

$0.41
+0.01 (+1.28%)
(As of 12:25 PM ET)
Compare
Today's Range
$0.40
$0.42
50-Day Range
$0.38
$0.54
52-Week Range
$0.36
$1.99
Volume
211,009 shs
Average Volume
579,810 shs
Market Capitalization
$52.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.80

Clene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,822.6% Upside
$7.80 Price Target
Short Interest
Healthy
0.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$102,501 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

381st out of 958 stocks

Pharmaceutical Preparations Industry

131st out of 393 stocks


CLNN stock logo

About Clene Stock (NASDAQ:CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CLNN Stock Price History

CLNN Stock News Headlines

Insider Spends US$103k Buying More Shares In Clene
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Benchmark Co. Keeps Their Buy Rating on Clene (CLNN)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Clene Inc. (CLNN) Interactive Stock Chart - Yahoo Finance
Clene Inc. Is 'One to Watch'
See More Headlines
Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/11/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLNN
Fax
N/A
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.80
High Stock Price Target
$13.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,850.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-29,920,000.00
Net Margins
-5,624.65%
Pretax Margin
-5,624.65%

Debt

Sales & Book Value

Annual Sales
$718,000.00
Book Value
$0.04 per share

Miscellaneous

Free Float
94,257,000
Market Cap
$51.37 million
Optionable
Not Optionable
Beta
0.53
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Robert Etherington MBA (Age 56)
    CEO, President & Director
    Comp: $590.98k
  • Mr. Morgan R. Brown CPA (Age 55)
    M.B.A., Chief Financial Officer
    Comp: $374.05k
  • Mr. Mark G. Mortenson ESQ. (Age 65)
    Chief Science Officer
    Comp: $482.98k
  • Mr. Jerry Miraglia J.D.
    General Counsel & Corporate Secretary
  • Mr. Michael T. Hotchkin
    Chief Development Officer
  • Ms. Mary Anne Mcneil
    Head of Human Resources
  • Dr. Benjamin M. Greenberg M.D.
    M.H.S., Head of Medical














CLNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Clene stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares.
View CLNN analyst ratings
or view top-rated stocks.

What is Clene's stock price target for 2024?

6 brokers have issued 12 month price objectives for Clene's stock. Their CLNN share price targets range from $4.00 to $13.00. On average, they expect the company's share price to reach $7.80 in the next twelve months. This suggests a possible upside of 1,822.6% from the stock's current price.
View analysts price targets for CLNN
or view top-rated stocks among Wall Street analysts.

How have CLNN shares performed in 2023?

Clene's stock was trading at $1.00 on January 1st, 2023. Since then, CLNN shares have decreased by 59.4% and is now trading at $0.4057.
View the best growth stocks for 2023 here
.

When is Clene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our CLNN earnings forecast
.

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) released its earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.08. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.14 million. Clene had a negative trailing twelve-month return on equity of 322.31% and a negative net margin of 5,624.65%.

Who are Clene's major shareholders?

Clene's stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (4.52%), Vivo Capital LLC (2.06%), Worth Venture Partners LLC (1.09%), Silverarc Capital Management LLC (0.39%), AE Wealth Management LLC (0.13%) and Kepos Capital LP (0.10%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman.
View institutional ownership trends
.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLNN) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -